Factor-XIIIa-positive dendrocytes belong to the monocyte-macrophage-dendrocyte (MMD) lineage which is considered to play a pivotal role in the skin response to the immune response modifier imiquimod. The same cells are also boosted in low-grade graft-versus-host reaction (GVHR) with skin manifestations. Both conditions are characterized by specific epidermal damage. The aim of the present study was to compare them using immunohistochemistry to identify MMD subsets and other inflammatory cells in the dermis. We compared 3 cases of long-term (4, 9 and 11 months) imiquimod topical applications on normal skin, 25 low-grade GVHR controlled by immunosuppressive therapy and 25 control cases with normal skin. Compared to the normal dermis, cells of the MMD lineage were considerably boosted in the dermis of GVHR and at the imiquimod-treated sites. By contrast, only minimal accumulations of lymphocytes and Langerhans cells were disclosed in the dermis. The pattern of dermal infiltration by MMD cells was similar in GVHR and after imiquimod treatment. However, intraindividual differences in densities were obvious irrespective of the skin condition. In conclusion, there is great mimicry in the MMD involvement in the dermis during low-grade GVHR and after chronic applications of imiquimod.

Keywords:
Dendrocyte, Imiquimod, Graft-versus-host reaction
1.
Edwards L, Ferenczy A, Eron L, Baker D, Owens ML, Fox TL, Hougham AJ, Schmitt KA: Self-administered topical 5% imiquimod cream for external anogenital warts. Arch Dermatol 1998;134:25–30.
2.
Tyring SK, Arany I, Stanley MA: A randomised, controlled, molecular study of condyloma acuminata clearance during treatment with imiquimod. J Infect Dis 1998;178:551–555.
3.
Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML: Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999;41:1002–1007.
4.
Kaspari M, Gutzmer R, Kiehl P, Dumke P, Kapp A, Brodersen JP: Imiquimod 5% cream in the treatment of human papillomavirus-16-positive erythroplasia of Queyrat. Dermatology 2002;205:67–69.
5.
Maw RD, Kinghom GR, Bowman CA, Goh BT, Nayagam AT, Nathan M: Imiquimod 5% cream is an acceptable treatment option for external anogenital warts in uncircumcised males. J Eur Acad Dermatol Venereol 2002;16:58–62.
6.
Slade HB: Cytokine induction and modifying the immune response to human papilloma virus with imiquimod. Eur J Dermatol 1998;8:13–16.
7.
Perry CM, Lamb HM: Topical imiquimod: A review of its use in genital warts. Drugs 1999;58:375–390.
8.
Stanley MA: Mechanism of action of imiquimod. Papillomavirus Rep 1999;10:23–29.
9.
Wagner TL, Ahonen CL, Couture AM, Gibson SJ, Miller RL, Smith RM, Reiter MJ, Vasilakos JP, Tomai MA: Modulation of Th1 and Th2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell Immunol 1999;191:10–19.
10.
Dockrell DH, Kinghorn GR: Imiquimod and resiquimod as novel immunomodulators. J Antimicrob Chemother 2001;48:751–755.
11.
Hermanns-Lê T, Nikkels AF, Uhoda I, Petit L, Piérard GE: Imiquimod (Aldara®): An immune response modifier for the skin. Rev Med Liège 2002;57:116–118.
12.
Arany I, Tyring SK, Brysk MM, Stanley MA, Tomai MA, Miller RL, Smith MH, McDermott DJ, Slade HB: Correlation between pretreatment levels of interferon response genes and clinical responses to an immune response modifier (imiquimod) in genital warts. Antimicrob Agents Chemother 2000;44:1869–1873.
13.
Burns RP, Ferbel B, Tomai M, Miller M, Gaspari AA: The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans’ cells. Clin Immunol 2000;94:13–23.
14.
Suzuki H, Wang B, Shivji GM, Toto P, Amerio P, Tomai MA, Miller RL, Sauder DN: Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 2000;114:135–141.
15.
Wagner TL, Ahonen CL, Couture AM, Gibson SJ, Miller RL, Smith RM, Reiter MJ, Vasilakos JP, Tomai MA: Modulation of Th1 and Th2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell Immunol 1999;191:10–19.
16.
Tomai MA, Imbertson LM, Stanczak TL, Tygrett LT, Waldschmidt TJ: The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes. Cell Immunol 2000;203:55–65.
17.
Arrese JE, Piérard GE: Factor-XIIIa-positive dendrocytes and the dermal microvascular unit. Dermatologica 1990;180:51–53.
18.
Al-Saleh W, Delvenne P, Arrese JE, Nikkels AF, Piérard GE, Boniver J: Inverse modulation of intraepithelial Langerhans’ cells and stromal macrophage/dendrocyte populations in human papillomavirus-associated squamous intraepithelial lesions of the cervix. Virchows Arch 1995;427:41–48.
19.
Nestle FO, Nickoloff BJ: A fresh morphological and functional look at dermal dendritic cells. J Cutan Pathol 1995;22:385–393.
20.
Arrese JE, Paquet P, Claessens N, Piérard-Franchimont C, Piérard GE: Dermal dendritic cells in anogenital warty lesions unresponsive to an immune-response modifier. J Cutan Pathol 2001;28:131–134.
21.
Lampert IA, Janossy G, Suitters A, Bofill M, Palmer S, Gordon-Smith E, Prentice HG, Alero-Thomas J: Immunological analysis of the skin in graft versus host disease. Clin Exp Immunol 1982;50:123–131.
22.
Facon T, Jouet JP, Noel Walter MP, Lai JL, Jabinet JL, Chambon JP, Bauters F: Involvement of TNF-α secreting macrophages in lethal forms of human graft-versus-host disease. Bone Marrow Transplant 1987;20:511–515.
23.
Krenger W, Hill GR, Ferrara J: Cytokine cascades in acute graft-versus-host disease. Transplantation 1987;64:553–558.
24.
Nestel F, Price K, Seemayer T, Lapp W: Macrophage priming and lipopolysaccharide triggered release of TNF-alpha during graft versus host disease. J Exp Med 1992;175:405–413.
25.
Pimpinelli N, Romagnoli A, Alberto B, Santucci M, Mori M, Guidi S, Gianotti B: Dendritic cells in the skin after allogeneic bone marrow transplantation: Immunohistochemical and electron microscopy monitoring. Eur J Dermatol 1993;4:310–317.
26.
Facon T, Janin A, Noel MP, Jouet JP: Involvement of macrophages in lethal forms of graft-versus-host disease. Lancet 1995;345:398.
27.
Piérard GE, Nikkels-Tassoudji J, Arrese J, Nikkels AF, Piérard-Franchimont C: L1 protein in incipient lymphocyte-depleted graft-versus-host disease: Expression in keratinocytes and co-expression with factor XIIIa in dermal cells. Turk J Dermatopathol 1998;7:10–13.
28.
Yoo YH, Park BS, Whitaker-Menezes D, et al: Dermal dendrocytes participate in the cellular pathology of experimental acute graft-versus-host disease. J Cutan Pathol 1998;25:426–434.
29.
Ferrara J, Deeg HJ: Graft-versus-host disease. N Engl J Med 1999;324:667–674.
30.
Hermanns-Lê T, Paquet P, Piérard-Franchimont C, Arrese JE, Piérard GE: Regulatory function of factor-XIIIa-positive dendrocytes in incipient toxic epidermal necrolysis and graft-versus-host reaction. Dermatology 1999;198:184–186.
31.
Paquet P, Arrese JE, Beguin Y, Piérard GE: Clinicopathological differential diagnosis of drug-induced toxic epidermal necrolysis (Lyell’s syndrome) and acute graft-versus-host reaction; in Cerio R (ed): Current Topics in Pathology. Berlin, Springer, 2001, vol 94: Dermatopathology, pp 65–78.
32.
Paquet P, Nikkels A, Arrese J, Vanderkelen A, Piérard GE: Macrophages and tumor necrosis factor-α in toxic epidermal necrolysis. Arch Dermatol 1994;130:605–608.
33.
Piérard GE, Nikkels-Tassoudji N, Nikkels A, Arrese J, Piérard-Franchimont C, Jerusalem G, Beguin Y, Fillet G: Epidermal calprotectin expression in lymphocyte-depleted cutaneous graft-versus-host reaction. Arch Argent Dermatol 1998;48:139–142.
34.
Homey B, Alenius H, Muller A, Soto H, Bowman EP, Yuan W, McEvoy L, Lauerma AI, Assmann T, Bunemann E, Lehto M, Wolff H, Yen D, Marxhausen H, To W, Sedgwick J, Ruzicka T, Lehmann P, Zlotnik A: CCL-27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat Med 2002;8:157–165.
35.
Sueki H, Whitaker D, Buchsbaum M, Murphy GF: Novel interactions between dermal dendrocytes and mast cells in human skin: Implications for hemostasis and matrix repair. Lab Invest 1993;69:160–172.
36.
Walsh LJ, Trinchieri G, Waldorf HA, Whitaker D, Murphy GF: Human dermal mast cells contain and release tumor necrosis factor α, which induce endothelial leucocyte adhesion molecule 1. Proc Natl Acad Sci USA 1991;88:4220–4224.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.